Thymic Tumors clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Ivonescimab for the Treatment of Thymic Cancer

    open to eligible people ages 18 years and up

    This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Los Angeles, California

Our lead scientists for Thymic Tumors research studies include .

Last updated: